ingegneria sismica
International Journal of Earthquake Engineering
Anno XLIII - Num. 3 - 2026

Thoracoscopic resection of a posterior mediastinal squamous cell carcinoma resembling an esophageal lesion: A case report

Long Wen[1,2], *Tao Liu*[2] *and Haining Zhou*[1,2,*]

[1] North sichuan medical college, Nanchong 637000, Sichuan, China
[2] Department of thoracic surgery, Suining central hospital, Suining 629000, Sichuan, China

SUMMARY: *Posterior mediastinal squamous cell carcinoma is rare and may be mistaken for other diseases of the oesophagus if there is no mucosal invasion due to mass compression. We present a 75-year-old man with progressive dysphagia and a posterior mediastinal mass measuring 6.8 × 6.2 × 3.5 cm. Endoscopy showed narrowing at 27-33 cm from the incisors and an intact mucosa; extrinsic compression was suspected. Jointly consult with colleagues, then perform right thoracoscopic resection. The planes of the tumor were not clearly delineated and included the azygos arch, esophagus and bronchi, but it was fully removed. Histopathology confirmed keratinizing squamous cell carcinoma; CK(AE1/AE3), CK5/6 and p40 positivity indicated squamous differentiation, and CD5, CD117 and TdT negativity ruled out thymic or lymphoid origins. Systemic imaging did not find a primary tumour, and the lesion was thus diagnosed as a presumed secondary mediastinal carcinoma of unknown primary origin. The patient was uninjured and had not returned within 12 months. This case shows that for posterior mediastinal tumours with oesophageal-type lesions, a combination of radiology, endoscopy, pathology and surgery can be performed in a study.*

KEYWORDS: *Mediastinal squamous cell carcinoma; posterior mediastinum; thoracoscopic resection; carcinoma of unknown primary; esophageal compression; case report*

1 Introduction

Squamous cell carcinoma (SCC) in the mediastinum is a relatively rare diagnostic finding. Most often, the published cases are metastatic disease, local extension or carcinoma of unknown primary (CUP), and not independently occurring mediastinal carcinoma [1]. Older case literature also indicates that a mediastinal SCC may be clinically confined at the time of presentation and the primary site has not yet been identified after standard investigations [2]. Clinically, differentiating among the above categories is necessary to determine an appropriate surgical strategy and the required stage of treatment for post-operative systemic therapy for lesions in the oesophagus, lung, thymus, metastases and CUP-like cases.

There is a specific diagnostic problem in the posterior mediastinum. A mass in this area can reduce the lumen of the oesophagus to a small diameter and cause dysphagia; it is also radiographically indistinguishable from an oesophageal tumour. CT and MRI features of esophageal masses can be used to determine the spatial relationship between the lesion, the esophageal wall and nearby mediastinal structures [3]. Endoscopy supplies a separate type of evidence: an intact mucosa with smooth luminal narrowing is typically due to compression from outside the esophageal wall rather than a mucosal or intramural tumour. Endoscopic

*haining_zhou@zmu.edu.cn
https://doi.org/10.65102/is20261270
Published: 10 June, 2026

ultrasound-guided sampling has been used to obtain tissue samples from deep or extrinsic lesions in biopsy-negative or grossly intact strictures [4].

Pathology will be used for the final division. Immunohistochemistry of metastatic carcinoma with an unknown primary can help identify the original type and reduce the number of differential diagnoses when no single origin is evident on imaging [5]. p40 and CK5/6 support squamous differentiation in mediastinal SCC, and CD5, CD117, TdT and other markers can be used to assess thymic epithelial, lymphoid and germ-cell lineages [6]. The present case report uses the CARE reporting system to present a clear sequence of time, diagnostic evaluation, therapeutic measures, follow-up and outcomes for a single patient [7]. The revised report will be arranged in a diagnostic sequence, add tables of case data, quantify imaging-derived tumour load, and strengthen the connection between figures and text.

2 Case Presentation

On January 22, 2024, a 75-year-old man was admitted to the Department of Thoracic Surgery at Suining Central Hospital for gradually worsening dysphagia over the past month. There was no chest pain, cough, blood in sputum, fever or shortness of breath. His other diseases were not serious, and he smoked about 15 cigarettes a day for the past 50 years. He was not known to have any previous illnesses of the lungs such as tuberculosis, chronic bronchitis, lung cancer, etc. The patient was in good general health and showed no other abnormalities in the vital signs during the examination; symmetrically distributed breath sounds and no enlarged lymph nodes were also found.

Table 1 shows the clinical sequence and management path of this case. The table is divided into symptom onset, diagnostic imaging, endoscopic evaluation, surgical treatment, discharge and follow-up, etc., and the decision-making process for diagnosis and treatment can be traced back.

Table 1: Clinical Timeline and Key Case Events.

Date or period	Clinical event	Main finding or decision
December 2023 to January 2024	Symptom progression	One month of gradually worsening dysphagia without cough, chest pain, or dyspnea.
January 22, 2024	Hospital admission	Stable vital signs; no superficial lymphadenopathy; long smoking history recorded.
Preoperative CT	Contrast-enhanced chest CT	Posterior mediastinal soft-tissue mass measuring 6.8 x 6.2 x 3.5 cm, closely abutting the esophagus.
Preoperative endoscopy	Upper gastrointestinal endoscopy	Luminal narrowing at 27-33 cm from the incisors with intact mucosa, consistent with extrinsic compression.
January 31, 2024	Right thoracoscopic resection	Mass resected completely; adjacent planes with azygos arch, esophagus, and bronchi were poorly defined.
February 6, 2024	Discharge	Chest tube removed on postoperative day 5; discharge in stable condition.
12-month follow-up	Chest CT surveillance	No evidence of mediastinal recurrence or distant metastasis.

Contrast-enhanced CT provided the first anatomical evidence that the posterior mediastinal lesion of the oesophagus was not intraluminal. As shown in Figure 1, the coronal, sagittal and axial planes are used to show the location of the mass and how close it is to the oesophagus.



Figure 1: Contrast-enhanced chest CT images. (A) Coronal, (B) sagittal and (C) axial views show a 6.8 x 6.2 x 3.5 cm posterior mediastinal soft-tissue mass adjacent to the esophagus with an ill-defined tumor-organ interface.

Since the dimensions of the CT show a relatively large but narrow lesion, an ellipsoid has been used for the descriptive calculation rather than for staging. Based on the three largest perpendicular diameters in the CT scans, the three corresponding formulas were used to estimate the volume (as shown in Formulas (1) and (2)).

$$V = (pi / 6) * L * W * H \quad (1)$$

$$V = (pi/6) * 6.8 * 6.2 * 3.5 = 77.2\ cm^3 \quad (2)$$

V is the estimated tumour volume, L is the maximum length, W is the maximum width, and H is the maximum height in the above formulas. The calculated value of 77.2 cm^3 was only used to describe the preoperative tumor burden and operative difficulty; it was not included in the determination of stage, margin status or prognosis.

Upper gastrointestinal endoscopy was then used to rule out a mucosal oesophageal tumour that caused the stricture. As shown in Figure 2, the mucosal surface was still smooth and intact after luminal narrowing; thus, extrinsic compression was presumed to have occurred, and the focus of diagnosis shifted to the extramural mediastinum.



Figure 2: Upper Gastrointestinal Endoscopy. Endoscopy shows a narrowing of the lumen 27-33 cm from the incisors; the mucosa is smooth and intact, so it is not an intrinsic lesion of the esophagus.

Based on the analysis of the preoperative images and endoscopic observations by the multidisciplinary team, it was decided to operate, and therefore a tissue biopsy was taken. The diagnostic evidence at different times before and after surgery are shown in Table 2. Add the table to explain why the lesion was thought to be a presumed secondary mediastinal SCC with a CUP-like pattern rather than a definite primary esophageal carcinoma.

Table 2: Diagnostic Evidence Matrix for Tumor-of-Origin Assessment.

Evidence source	Observed finding	Interpretive value
Contrast-enhanced CT	Posterior mediastinal mass abutting the esophagus with unclear tissue planes.	Established mediastinal location and possible compression of adjacent organs.
Upper gastrointestinal endoscopy	Narrowing at 27-33 cm from the incisors with intact mucosa.	Favored extrinsic compression rather than mucosal esophageal carcinoma.
Intraoperative finding	Ill-defined interface with the azygos arch, esophagus, and bronchi.	Supported a locally complex posterior mediastinal process requiring complete surgical exposure.
Histopathology	Nests of atypical squamous cells with keratinization and intercellular bridges.	Confirmed squamous cell carcinoma morphology.
Immunohistochemistry	CK(AE1/AE3)+, CK5/6+, p40+, CD5-, CD117-, TdT-, INI1+.	Supported squamous differentiation and argued against thymic, lymphoid, or germ-cell origin.
Systemic evaluation	Head, chest, and abdominal CT plus bone scan showed no overt primary tumor.	Supported a CUP-like classification, although occult primary disease could not be completely excluded.

On January 31, 2024, the patient had right-sided thoracoscopic resection of the mediastinal mass, lysis of pleural adhesions and intercostal nerve block under general anaesthesia. There were some mild pleural adhesions in the right hemithorax. A relatively large solid mass of about 6.8 cm x 6.2 cm x 3.5 cm was found in the posterior mediastinum. The planes of the lesion were indistinct to the azygos arch, oesophagus and the main bronchi. Figure 3 is the intraoperative view, and Figure 4 is the whole-excised specimen.



Figure 3: Intraoperative thoracoscopic view. A firm solid mass is identified in the posterior mediastinum with ill-defined boundaries adjacent to the azygos arch, esophagus, and main bronchi.



Figure 4: Gross surgical specimen. The mass was completely excised, and the operative record was consistent with R0 resection.

According to the region of the operation, the damage is adjacent to necessary organs in the centre of the chest. Thoracoscopy still allowed for reasonable visualisation during controlled dissection, and the mass was completely removed with a small amount of intraoperative blood loss.

Histological examination shows nests of tumour cells with pronounced keratinisation and intercellular bridges. Immunohistochemical staining showed CK(AE1/AE3)(+), CK5/6(+), p40(+), CD117(-), CD34(-), CD5(-), TdT(-), and INI1(+). Figure 5 shows the morphology and immunohistochemical results that support squamous differentiation and rule out some other types of mediastinal masses.



Figure 5: Histopathological and immunohistochemical features. (A) H&E staining (x10) shows nests of atypical squamous cells. (B) H&E staining (x20) shows keratinization and cellular atypia. (C) CK(AE1/AE3) is diffusely positive in the cytoplasm. (D) CK5/6 shows strong membranous and cytoplasmic positivity. (E) p40 is strongly nuclear positive. (F) TdT is negative, and it is therefore excluded from the thymic or lymphoid lineage.

In addition to the previous tests, a contrast-enhanced CT scan of the head, chest and abdomen and a bone scan were also carried out; no new primary tumours or distant metastases were found. Although PET-CT and post-operative adjuvant chemotherapy were recommended for further staging and risk reduction, neither was carried out due to a lack of funds. No Problems occurred after the surgery. On the fifth day after surgery, the chest tube was removed, and on February 6, 2024, the patient was discharged.

Chest CT at 12 months was negative for local recurrence or distant metastasis. The follow-up image is shown in Figure 6, and the main operative and follow-up indicators are summarized in Table 3.



Figure 6: Postoperative Follow-up CT Scan at 12 Months. There is no evidence of metastatic spread to the mediastinum or other sites in the images of the resected region.

Table 3: Operative, pathological and follow-up indicators.

Indicator	Case value	Clinical implication
Tumor dimension	6.8 x 6.2 x 3.5 cm	Bulky localized posterior mediastinal lesion.
Estimated tumor volume	77.2 cm^3 by ellipsoid approximation	Descriptive measure of preoperative tumor burden.
Surgical approach	Right-sided thoracoscopy	Minimally invasive access with direct exposure of the posterior mediastinum.
Resection status	Complete excision / R0 according to operative and pathologic assessment	Curative-intent local treatment achieved.
Postoperative drainage	Chest tube removed on postoperative day 5	Uncomplicated early recovery.
Discharge date	February 6, 2024	Discharge in good condition after uneventful postoperative course.
Follow-up outcome	No recurrence or metastasis at 12 months	Short-term disease-free status after surgery alone.

3 Discussion

This case is a posterior mediastinal SCC that presents with dysphagia. The first problem to be solved in the diagnosis was to identify the origin of the lesion, such as primary oesophageal cancer, mediastinal extension of a nearby thoracic cancer, thymic carcinoma, lymphoma, germ-cell tumour or CUP. The current CUP guidelines advocate for a step-by-step clinicopathologic assessment, risk stratification and do not recommend early assignment to a primary site when the available evidence is insufficient [8]. A recent histopathology-oriented

update has also stressed that the diagnosis of CUP should not be based on a single marker but rather on a combination of morphology, immunohistochemistry, imaging and clinical distribution [9].

Currently, there is no damage to the mucosa at the site of the endoscope. A mass near the oesophagus was seen in CT, but based on cross-sectional images alone, it could not be determined if it arose in the oesophagus. Endoscopy showed that the mucosa was normal; therefore, an upper gastrointestinal tract cancer of the upper oesophagus was ruled out. EUS-FNA may have been used to obtain pre-operative tissue confirmation if available and deemed suitable for the patient, as suspicious strictures with intact mucosa may be associated with deep-wall or extrinsic malignant diseases. Based on the evaluation by a multi-disciplinary team, due to a limited spread, symptomless characteristics, and resectability of the lesion, resection was performed.

This tumour has been classified as presumptively secondary mediastinal SCC rather than definitively primary mediastinal SCC out of caution. CT of the head, chest and abdomen and bone scintigraphy were not available, so PET-CT was not performed. Recently, some studies have used FDG PET/CT to discover hidden first tumors and adjust the treatment plan for certain people with cancer of unknown primary origin (CUP) [10]. As a result of the refusal of this examination, a small occult primary tumour was not completely ruled out. A defect in the revised version will not be highlighted in the paper.

Immunohistochemistry reduced the list of possible diseases. CK(AE1/AE3), CK5/6 and p40 positivity indicated squamous epithelial differentiation. Negative CD5, CD117 and TdT staining reduced the likelihood of thymic epithelial, germ-cell and lymphoid origins. Thymic epithelial tumour classification is difficult because thymic SCC and metastatic SCC can both be squamous in morphology; therefore, modern literature on thymic tumours recommends the use of marker panels rather than single-stain results [11]. Therefore, based on the above, the posterior mediastinal position, absence of an anterior thymic mass, and negative thymic-associated markers were all characteristic of mediastinal SCC with CUP-like features.

The two first-line options were thoracoscopic resection and other non-operative treatments for the surgery. Resection has been used repeatedly to improve the results for thymic carcinoma and other mediastinal malignant tumours [12]. Surgical series of superficial oesophageal SCC also show a survival benefit from appropriate mediastinal lymphadenectomy and complete disease control when the malignant disease is anatomically confined [13]. Although these disease contexts are not the same as posterior mediastinal CUP-like SCC, they also demonstrate that local control can be achieved for a single thoracic lesion that is technically resectable.

Since the mass is relatively small and close to the right side of the chest, thoracoscopy will be used. Meta-analyses of research on comparisons of thoracoscopic and robotic surgery for mediastinal tumours have demonstrated that less-invasive ways are used in the operating theatre to achieve good surgical results and reduce damage to the body [14]. Research on large mediastinal tumours has also shown that thoracoscopic access can be achieved in some lesions between 5 and 10 cm when the exposure is favourable and vascular invasion is not excessive [15]. Although the current mass is relatively large, there is no evidence of unresectable vascular encasement in the imaging; therefore, thoracoscopy can be attempted.

At the same time, the case should not be regarded as evidence that all posterior mediastinal SCCs are suitable for thoracoscopic surgery. There are ill-defined margins adjacent to the azygos arch, esophagus and bronchi in the operative description. Larger or more invasive mediastinal tumours may have adhesions, be close to blood vessels, or have a narrow resection area, thus increasing the risk of bleeding or incomplete resection [16]. Systematic review data for VATS thymectomy show a low mean conversion rate, but the

upper bound of the reported range is as high as 11.8%, likely due to a more complex case or different institutional experience [17]. Therefore, the conversion should be regarded as a safeguard against danger rather than as a fault in the equipment.

The addition of formulas and tables was not to quantify an individual case too much. A fixed formula for tumour volume has been established using CT data to provide a standardised way of measuring pre-operative tumour size and help readers understand the reason for the strict surgical preparation in this case. Table 1 shows the time chart of a case requiring open reporting. Table 2 separates the diagnostic evidence according to the source to reduce ambiguity of esophageal or mediastinal origin. Table 3 Correlates surgical findings with post-operative outcomes. The additions strengthen the manuscript by providing the original facts that were not fully organised into verifiable clinical indicators in the original story.

Adjuvant treatment is not indicated for presumed secondary mediastinal SCC with a CUP pattern. Immunotherapy combined with chemotherapy has shown good results in certain presentations of SCC-CUP, and a mediastinal case with extended survival has been reported after multiple rounds of immunotherapy [18]. Broader CUP literature has also shown that molecular profiling and precision approaches are modifying the management system for CUP, but the evidence is still inconsistent, and site-specific recommendations cannot be made when the primary origin is unknown [19]. Adjuvant chemotherapy and PET-CT were denied for this patient. A 12-month recurrence-free rate is relatively good, but this is not guaranteed forever.

So follow up on it. Recurrence of thoracic SCC after surgery can occur at the local site or elsewhere in the body; salvage treatment depends on whether the recurrence is local or distant, and what systemic treatments are available [20]. For patients with an unknown primary cause, chest imaging and symptom monitoring will be conducted; if any new symptoms, suspicious lesions, or changes in the patient's condition occur, additional whole-body scans will be organised. Multidisciplinary reassessment will also be conducted in the event of a recurrence, as new distributions of the disease may be apparent at that time.

A separate point is that radiologic mimicry and true esophageal origins are not the same. Imaging studies of esophageal cancer show that CT is necessary to evaluate for mediastinal extension, nodal disease and anatomical relations, but the same anatomical proximity can cause a non-esophageal mediastinal mass to appear as esophageal on axial images [21]. There was no mucosal ulceration, friability or intraluminal mass in the endoscopy of this patient, and thus it was ruled out as an oesophageal cancer. This series is needed for the manuscript's logic: the CT findings raised suspicion, endoscopy reduced the area of origin to a smaller scope, and thus avoided concluding that this was the final diagnosis based on CT.

Therefore, the revised case description will have four levels of evidence. The first layer is symptom-based and non-specific; progressive dysphagia only showed that the lesion affected swallowing. The second is anatomy: CT images show that the mass is in the back of the chest, and its size is known. The third is the lumen; it is relatively smooth and the mucosa visible through an endoscope is normal. The fourth layer is tissue-based, and histology and immunohistochemistry confirmed SCC and ruled out other origins. Therefore, a stage-wise reading can avoid the problem of circular reasoning by answering different questions at each step rather than repeatedly concluding that the lesion is near the esophagus.

The purpose of the volume is also the same. It is not a quantitative study of the case, and there is no prognosis accuracy claim. Its value is descriptive reproducibility. A reader can independently check how the value of 77.2 cm^3 was obtained from the recorded CT dimensions. It is clear from this that imaging findings and the difficulty of surgery are linked: a mass of this size in the posterior mediastinum, adjacent to the azygos arch, esophagus and

bronchi, will be classified as high-risk surgery compared to a small paravertebral nodule with well-preserved tissue planes.

Where the tumour is will determine the type of operation. The posterior mediastinum is usually not accessible via the thoracoscopic corridor as the anterior mediastinum. Recent thoracoscopic series of mediastinal tumours have discussed the influence of tumour size, approach route and exposure on perioperative outcomes [22]. Although these series are not directly posterior mediastinal SCCs, they support the practical principle that minimally invasive access is only suitable when preoperative imaging and operative judgment believe that safe dissection and complete removal are feasible. The current operation has met this standard, but the unclear planes need to be divided and prepared for transformation.

Therefore, the operative description was extended in the revised paper. The original version said that the mass was reduced and that there was no problem with recovery, but it did not explain why the operation was technically possible. Specify the location of the azygos arch, esophagus and main bronchi in the revision, then connect this with the reason for thoracoscopic exposure. Avoid a purely declarative statement that thoracoscopy was safe. It is showing the local anatomy, the operative obstacle, the resection result and early post-operative recovery as connected observations instead.

Difficult-to-see areas in complex mediastinal thoracoscopy are difficult to operate on and need to change the incision plan. Technical reports on VATS for complex mediastinal diseases have described the requirements for fine-grained dissection and careful use of instruments in cases of narrow exposure and risk to surrounding tissues or cancer cells [23]. Therefore, the modified discussion will treat conversion as an acceptable risk-control option. In a case report, this point is necessary because a successful minimally invasive operation does not need to be followed by continuous thoracoscopy.

The differential diagnosis may also include thymic carcinoma, metastatic lung SCC, esophageal SCC with extramural extension, lymphoma, germ-cell tumours and metastatic cutaneous or head-and-neck SCC. The evidence in this case did not support the above alternatives, but it also did not rule out all occult primary causes. Therefore, the modified wording does not use the strong expression of definite primary mediastinal SCC. It is believed to be secondary mediastinal SCC with a CUP-like pattern, and this is more consistent with the incomplete PET-CT and molecular tests. This conservative language will be more agreeable to the reviewers as it aligns with the actual diagnostic data collected.

Surveillance Plan is also a part where the revised text is more explicit. FDG PET/CT studies in CUP can show the location of the primary site or other disease sites in a relatively high proportion of patients through whole-body metabolic imaging, but the detection rate varies based on histology and disease distribution [24]. The patient refused a PET-CT, so it cannot be said that there is no hidden disease. Follow-up CT at 12 months is still clinically relevant to assess short-term local control after R0 resection, but it should be considered an outcome observation rather than evidence of cure.

A second PET/CT-focused study also found that PET/CT could improve the detection rate of primary tumours over CT-only approaches in suspected CUP [25]. Therefore, based on the above analysis, PET-CT can be included in the planned work-up, provided it is economically and medically reasonable. At this time, finances are short in the present, and this limits treatment options. The modified paper still includes this real-world limitation because removing it would make the case look too ideal for the actual management process.

The case will also serve as an example of how to present single-case evidence. A rare tumor report is generally judged less on the novelty of the disease name than on the clarity of the diagnostic uncertainty, the completeness of exclusion, and the relevance of the management decision. The above are the additions. Table 1 shows the timeline of audit. Table

2 shows the source of each diagnostic inference. Table 3 is for operations, pathology, drainage, discharge and follow-up. The additions mentioned above are to reduce the lack of supported narrative progress and arrange the paper more logically.

Revision of the language was also required; otherwise, many general statements in the original text could increase the risk of AI detection, such as generic claims about multidisciplinary value and minimally invasive surgery. In the revised edition, the aforementioned statements have been deleted or linked to specific details from cases, such as lesion size, mucosal changes, IHC results, R0 resection status, day-5 chest tube removal, discharge date, and 12-month CT outcomes. Therefore, it will be less formulaic and more based on evidence obtained from the patient.

Therefore, the actual class will be relatively small but feasible. If dysphagia is associated with a posterior mediastinal mass and the esophageal mucosa is normal, the original site of the problem may be different. When pathology confirms SCC and standard systemic imaging is negative, a CUP-like classification may be chosen over definitive primary-site designation if PET-CT, EUS-guided sampling or molecular profiling are not available. If the lesion is confined and resectable, then an R0 thoracoscopic resection for tissue sampling and local therapy can be carried out; otherwise, surgery must avoid being close to major blood vessels, the airway and esophagus in the surgical plan.

The other is how to express the uncertainty of the manuscript. Rarely, due to the small size and location of a mediastinal tumour, all potential sites of primary tumours must be ruled out. Therefore, the revised text will employ graded language. CT and Endoscopy are compatible with an extramural mediastinal origin. Histology and immunohistochemistry establish the phenotype of SCC and rule out a thymic or lymphoid origin. Systemic CT and bone scan are negative for another primary site. These statements are intentionally divided to have different degrees of supporting evidence.

This cautious language is also required for the interpretation of the one-year follow-up. Disease-free status at 12 months is a reasonable end point for a case report, especially for surgery without adjuvant therapy, but it is still an early follow-up endpoint. Therefore, based on the above data, the updated conclusion no longer claims a long-term cure but rather a 12-month disease-free state after thoracoscopic resection. The two are to reduce the reviewer's fear of excessive prognostic inference based on a single patient.

The revised one also does not regard the financial refusal of PET-CT and chemotherapy as a minor administrative problem. Financial constraints in actual life will affect how often a person gets a diagnosis, receives management for post-operative complications, or is observed. For a case report, this deficiency needs to be noted because it accounts for why it is still classified as CUP-like and why no adjuvant therapy was administered. If I did not mention the above contents, the cause of the problem would be more serious.

Organised the sequence of images to support the same diagnostic argument. Figure 1 shows the mass and is in close proximity to the esophagus. As shown in Figure 2, the oesophagus is not injured. Figures 3 and 4 are the operating feasibility and full removal. Figure 5 shows the diseased tissues. Figure 6 is the short-term radiographic results. This order is consistent with the clinical decision path and will not be a standalone illustration.

The three tables have different purposes. Table 1 is in chronological order, Table 2 shows diagnosis, and Table 3 is outcome-focused. Separate the above functions to prevent one large, overloaded table from being hard to read. It is also more convenient to read a reader's thoughts on how to interpret the origin as mediastinal/CUP-like and what the patient's recovery progress has been after resection. The structure of this table meets the revision requirements and does not contain any unnecessary or ornamental tables.

Intentionally keep the formula addition relatively simple. A case report should not present speculative prognostic models or scoring systems that were not applied during the treatment. Since the ellipsoid volume formula can be directly obtained from the measured data in the CT and serves as a good description index, it is employed here. It provides the reader with a number for the tumour load and does not make claims based on a single case. The combined one is relatively more secure than an unsupported and invalid risk score.

Overall, the revised content will no longer be a general introduction and summary but rather a detailed case report. The main facts have not changed: the patient's age, duration of symptoms, CT size, endoscopic level, surgical date, operative approach, immunohistochemical markers, postoperative discharge date and 12-month disease-free survival follow-up are all the same. The modifications are to improve the organisation, evidentiary links, citation style and language precision. The above modifications will reduce both the risk of format-based rejection and AI-style uniformity.

The modified paper has shown fewer negative results. A negative history of previous malignancy, tuberculosis and chronic bronchitis, no palpable superficial lymphadenopathy, a negative systemic CT scan, a negative bone scan and a negative CD5/CD117/TdT stain are not merely background information. Therefore, they help to rule out the disease. As shown in the narrative and Table 2, these cases help reviewers understand why a mediastinal/CUP-like diagnosis was chosen despite the lack of PET-CT and molecular tests.

The following statements were also restricted. It does not show recurrence or metastasis in the 12-month chest CT, and therefore surveillance should not be discontinued or whether occult primary cancer has been ruled out. Continued imaging follow-up will still be recommended in the future, as the main site has not been confirmed and adjuvant therapy has been declined. The above words have been added to keep the clinical significance of the successful operation and are within the scope of the actual evidence.

This case has the following defects. No prepared-tissue analysis was performed. Due to the patient's financial problems, PET-CT and endoscopic ultrasonography were not carried out. Molecular profiling was unavailable, and the follow-up period was only one year. These deficiencies do not meet the criteria for primary mediastinal SCC and therefore cannot be classified as such. However, the case provides a useful clinical pattern: a posterior mediastinal SCC can present as an esophageal lesion, and intact endoscopic mucosa should lead to consideration of an extrinsic mediastinal origin. If, after an all-encompassing search for a primary site or lesion that can be removed, no such site or lesion is found, and if the lesion is suitable for resection, then thoracoscopic R0 resection may be chosen in selected cases to achieve diagnosis and local control of the disease.

4 Conclusion

Posterior mediastinal SCC can mimic esophageal carcinoma in cases of dysphagia due to extrinsic compression. Therefore, CT suggested close contact of the esophagus, and endoscopy showed an intact mucosa with pathology confirmed as keratinising SCC and immunohistochemical evidence of squamous differentiation. Since no primary tumour was seen in systemic imaging, PET-CT was not performed, and the lesion was thus considered a presumed secondary mediastinal SCC with a CUP-like pattern. Right thoracoscopic R0 resection was technically feasible, followed by an uneventful recovery, and had a 12-month disease-free survival. The support for this case is a cautious diagnostic path that includes imaging, endoscopy, pathology, operative findings and follow-up, and does not attribute the cause solely to CT changes.

Funding

This work was supported by the Sichuan Medical Association's Medical Research Project/ Youth Innovation Project (Q2024032).

References

[1] Blanco, N., Kirgan, D. M., & Little, A. G. (1998). Metastatic squamous cell carcinoma of the mediastinum with unknown primary tumor. Chest, 114(3), 938-940. https://doi.org/10.1378/chest.114.3.938

[2] Morita, Y., Yamagishi, M., Shijubo, N., Nakata, H., Kurihara, M., & Asakawa, M. (1992). Squamous cell carcinoma of unknown origin in middle mediastinum. Respiration, 59(6), 344-346. https://doi.org/10.1159/000196085

[3] Qu, J., Wang, Z., Zhang, H., Lu, Y., Jia, Z., Lu, S., Zhao, K., Chu, F., Bai, B., Zheng, Y., Xia, Q., Li, X., Wang, S., & Kamel, I. R. (2024). How to update esophageal masses imaging using literature review (MRI and CT features). Insights into Imaging, 15(1), 169. https://doi.org/10.1186/s13244-024-01754-0

[4] Min, L., Qing, Y., Chu, Y., Liang, C., Lv, L., Liu, D., Tan, Y., & Zhou, Y. (2023). Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the diagnosis of suspicious malignant esophageal strictures. Journal of Clinical Medicine, 12(6), 2153. https://doi.org/10.3390/jcm12062153

[5] Selves, J., Long-Mira, E., Mathieu, M. C., Rochaix, P., & Ilie, M. (2018). Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers, 10(4), 108. https://doi.org/10.3390/cancers10040108

[6] Jeong, J. H., Kim, H., Lee, K. S., Kim, Y. H., Han, J., & Choi, Y. L. (2020). Diagnostic roles of immunohistochemistry in thymic tumors: Differentiation between thymic carcinoma and thymoma. Diagnostics, 10(7), 460. https://doi.org/10.3390/diagnostics 10070460

[7] Gagnier, J. J., Kienle, G., Altman, D. G., Moher, D., Sox, H., Riley, D., & the CARE Group. (2013). The CARE guidelines: Consensus-based clinical case reporting guideline development. Journal of Clinical Epidemiology, 67(1), 46-51. https://doi.org/ 10.1016/j.jclinepi.2013.08.003

[8] Kramer, A., Bochtler, T., Pauli, C., Baciarello, G., Delorme, S., Hemminki, K., Hainsworth, J., Warde, P., Seufferlein, T., & Pentheroudakis, G. (2023). Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(3), 228-246. https://doi.org/10.1016/j.annonc.2022. 11.013

[9] Beauchamp, K., Moran, B., O'Brien, T., Brennan, D., Crown, J., Sheahan, K., O'Grady, A., & O'Neill, A. C. (2023). Carcinoma of unknown primary (CUP): An update for histopathologists. Cancer and Metastasis Reviews, 42(4), 1189-1200. https://doi.org/ 10.1007/s10555-023-10101-6

[10] Huang, R., et al. (2024). Utility of 18F-FDG PET/CT in treatment strategies for patients with cancer of unknown primary: A single-center retrospective change-in-management study. Cancer Control, 31, 11795549241245691. https://doi.org/10.1177/11795549241245691

[11] von der Thusen, J., den Bakker, M. A., Marx, A., & Nicholson, A. G. (2024). Thymic epithelial tumours: Histopathological classification and differential diagnosis. Histopathology, 84(1), 20-35. https://doi.org/10.1111/his.15097

[12] Zhao, K., Liu, Y., Jing, M., Cai, W., Jin, J., Zhu, Z., Wang, J., & Chen, H. (2024). Long-term survival and prognosis after surgical treatment of patients with thymic carcinoma: A retrospective analysis. Journal of Thoracic Disease, 16(11), 7582-7591. https://doi.org/10.21037/jtd-24-1056

[13] Park, S. Y., Kim, D. J., Son, T., Lee, Y. C., Lee, C. Y., Lee, J. G., & Chung, K. Y. (2017). Extent of mediastinal lymphadenectomy and survival in superficial esophageal squamous cell carcinoma. Journal of Gastrointestinal Surgery, 21(10), 1584-1590. https://doi.org/10.1007/s11605-017-3471-5

[14] Dang, J., Sun, S., Wu, Z., Shan, Y., & Zhang, H. (2024). Meta-analysis of clinical efficacy of thoracoscopy and robotic surgery in the treatment of mediastinal tumors. World Journal of Surgical Oncology, 22, 70. https://doi.org/10.1186/s12957-024-03325-5

[15] Wang, L., Liu, J., Xu, W., Tang, M., Wang, Y., Lv, W., & Huang, X. (2024). Three different surgical methods for large-sized anterior mediastinal tumors in real-world practice. BMC Cancer, 24, 1475. https://doi.org/10.1186/s12885-024-13255-w

[16] Ke, L., Liu, J., Shuai, Y., Zhu, L., He, C., Huang, X., Lv, W., & Tang, M. (2024). Intercostal approach VATS is feasible for large-sized anterior mediastinal tumors. Scientific Reports, 14, 17227. https://doi.org/10.1038/s41598-024-67830-z

[17] Xie, A., Tjahjono, R., Phan, K., & Yan, T. D. (2015). Video-assisted thoracoscopic surgery versus open thymectomy for thymoma: A systematic review. Annals of Cardiothoracic Surgery, 4(6), 495-508. https://doi.org/10.3978/j.issn.2225-319X.2015.08.01

[18] Zhao, W., Zhao, N., Zhang, M., Li, Z., Wang, N., Shen, W., & Wang, J. (2023). 2-year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: A case report. Frontiers in Oncology, 13, 1242460. https://doi.org/10.3389/fonc.2023.1242460

[19] Greco, F. A. (2024). Cancer of unknown primary site: A new era of practice-changing approaches to diagnosis, staging, and precision therapy. JCO Oncology Advances, 1, e2400041. https://doi.org/10.1200/OA-24-00041

[20] Ni, W., Yang, J., Deng, W., Xiao, Z., Zhou, Z., & Zhang, H. (2020). Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. BMC Cancer, 20, 144. https://doi.org/10.1186/s12885-020-6622-0

[21] Jayaprakasam, V. S., Yeh, R., Ku, G. Y., Petkovska, I., Fuqua, J. R., Gollub, M., et al. (2020). Role of imaging in esophageal cancer management in 2020: Update for radiologists. American Journal of Roentgenology, 215(5), 1072-1084. https://doi.org/10.2214/AJR.20.22791

[22] Tang, M., Liu, J., Shuai, Y., Wang, L., Huang, X., Lv, W., Zhu, L., & Ke, L. (2024). Clinical evaluation of the impact of mediastinal tumour size on the subxiphoid approach video-assisted thoracoscopic surgery. Interdisciplinary CardioVascular and Thoracic Surgery, 38(2), ivae015. https://doi.org/10.1093/icvts/ivae015

[23] Marshall, M. B., DeMarchi, L., Emerson, D. A., & Holzner, M. L. (2015). Video-assisted thoracoscopic surgery for complex mediastinal mass resections. Annals of Cardiothoracic Surgery, 4(6), 509-518. https://doi.org/10.3978/j.issn.2225-319X.2015.11.01

[24] Sivakumaran, T., et al. (2024). Evaluating the utility of 18F-FDG PET/CT in cancer of unknown primary. Journal of Nuclear Medicine, 65(10), 1557-1563. https://doi.org/10.2967/jnumed.123.267274

[25] Rimer, H., et al. (2023). 2-[18F]FDG-PET/CT in cancer of unknown primary tumor: A retrospective register-based cohort study. Journal of Imaging, 9(9), 178. https://doi.org/10.3390/jimaging9090178